Evidence map›Paper›PMID 39273644›Full record

ArticleInternational journal of molecular sciences2024

In Vitro Spectroscopic Investigation of Losartan and Glipizide Competitive Binding to Glycated Albumin: A Comparative Study.

Agnieszka Szkudlarek

Abstract readComparative Study
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Agnieszka SzkudlarekDepartment of Physical Pharmacy, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia in Katowice, 40-055 Katowice, Poland.ORCID 0000-0002-6891-9625

Funding

Medical University of Silesia PCN-2-012/K/1/FMedical University of Silesia PCN-2-013/K/2/F
6 · The paper itself

Abstract

Understanding the interaction between pharmaceuticals and serum proteins is crucial for optimizing therapeutic strategies, especially in patients with coexisting chronic diseases. The primary goal of this study was to assess the potential changes in binding affinity and competition between glipizide (GLP, a second-generation sulfonylurea hypoglycemic drug) and losartan (LOS, a medication commonly prescribed for hypertension, particularly for patients with concurrent diabetes) with non-glycated (HSA) and glycated (gHSA

Indexed as

Binding, CompetitiveGlipizideGlycated Serum AlbuminLosartanProtein BindingSerum AlbuminBinding SitesCircular DichroismGlycation End Products, AdvancedHumansHypoglycemic AgentsSerum Albumin, HumanSpectrometry, FluorescenceGlipizideGlycated Serum AlbuminGlycation End Products, AdvancedHypoglycemic AgentsLosartanSerum AlbuminSerum Albumin, HumanAGEsdiabetesdrug–albumin bindingdrug–drug interactionsglipizideglycated albuminlosartanpolypharmacotherapyspectroscopic investigation

Identifiers

PMID39273644
PMCPMC11395140

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.